Skip to main content

Hiv-1 reverse transcriptase inhibitor and its consequences for viral virulence

Objective

VIRULENCE will provide a strategy against a major health threat: occurrence of resistance against therapeutic HIV/AIDS-measures. Reverse transcriptase inhibitors play an essential role HIV -treatment RT variants with reduced susceptibility to these inhibitors emerge even under potent combination therapies and may become less virulent. Thus, emergence of RTI resistance negatively affects the inhibitor efficacy but may also result in virus variants with reduced pathogenicity. VIRULENCE aims at elucidating clinical consequences of changes in viral fitness for optimal use of antiviral drugs. VIRULENCE is first to address this through development and validation of improved fitness assays and their application on existing well-defined longitudinal clinical cohorts. The mol. mechanisms for viral fitness and resistance will be elucidated and new compounds active against drug resistant HIV will be defined. This integrated approach will improve care of patients with limited therapeutic options.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITY MEDICAL CENTRE UTRECHT
Address
Heidelberglaan 100
3584CX Utrecht
Netherlands

Participants (7)

ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
Address
Meibergdreef 15
1105AZ Amsterdam
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Hopital Bichat-claude Bernard, Rue H. Huchard
75018 Paris
INTITUTE DE RECERCA DE LA SIDA
Spain
Address
Ctra De Canyet, S/n. University Hospital Germans T
08916 Badalona
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
10,Minderbroedersstraat 10
3000 Louvain / Leuven
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Address
Roosevelt Drive Headington
OX3 7BN Oxford/headington
THE UNIVERSITY OF MILANO
Italy
Address
L. Sacco Hospital, Via Gb Grassi 74
20157 Milano
UNIVERSITY OF ERLANGEN-NUREMBERG
Germany
Address
4,Schlossgarten 4
91054 Erlangen